Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A significant association was found between CDH1 -160C/A (rs16260) and Exo1 (rs1047840, K589E) polymorphisms and prostate cancer risk.
|
30880589 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Herein, we evaluated the E-cadherin protein and gene expression in canine PC compared to normal tissues.
|
31850082 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to detect the SARI and E-cadherin protein expression in the prostate cancer and benign prostatic hyperplasia specimens, and their correlation was established.
|
31276688 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
A total of seven hub genes, including phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase (PAICS), cadherin 1 (CDH1), SRC proto‑oncogene, non‑receptor tyrosine kinase, twist family bHLH transcription factor 1 (TWIST1), ZW10 interacting kinetochore protein (ZWINT), PCNA clamp associated factor (KIAA0101) and androgen receptor, among which, five (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) were significantly upregulated and negatively correlated with miR‑1, were identified as key miR‑1 target genes in PCa.
|
30365107 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression.
|
29536528 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
Several of the affected genes were known to be associated with aggressive prostate cancer such as loss of PTEN, CDH1, BCAR1 and gain of MYC.
|
29295717 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, CNV in miR-15a, CDH1 and ZFHX3 were associated with presence of incidental prostate cancer (<i>p</i> = 0.023, 0.003, 0.025, respectively).
|
28915599 |
2017 |
Malignant neoplasm of prostate
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
DNA methylation level of the E-Cadherin gene could be an important predictive index for malignancy of prostate cancer.
|
27420993 |
2016 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We aim to systematically evaluate the potential of promoter methylation and polymorphism in E-cadherin gene to confer a risk to prostate cancer through meta-analysis.
|
25056535 |
2014 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Consequently, knockdown of SATB1 in highly aggressive human prostate cancer PC-3M cells inhibited invasiveness and tumor growth in vivo along with increase in E-cadherin protein expression.
|
23308245 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We have shown previously that cancer prevention by cruciferous vegetable constituent phenethyl isothiocyanate (PEITC) in a transgenic mouse model of prostate cancer is associated with induction of E-cadherin protein expression.
|
23682784 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.
|
22581815 |
2012 |
Malignant neoplasm of prostate
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Several genes including CDH1 previously reported as methylation markers in PCa were not confirmed in our study.
|
21694441 |
2011 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis.
|
18781193 |
2009 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The presence of the A allele of the -160C/A polymorphism in the E-cadherin gene may be a risk factor for prostate cancer in the Japanese population.
|
17656222 |
2007 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients.
|
17138130 |
2007 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inherited variation in RNASEL, MSR1 and E-cadherin genes do not seem to contribute to prostate cancer development in Poland.
|
17627168 |
2007 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men.
|
16813949 |
2006 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
The E-cadherin (CDH1) gene has been implicated in prostate cancer (PCA) risk, however, the exact mechanism is unknown.
|
16372334 |
2006 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The distribution of the CDH-1 gene CC genotype in prostate cancer patients (51.0%) was higher than in the controls (10.5%).
|
16327305 |
2005 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Seven SNPs, including the promoter SNP rs16260, that captured over 96% of CDH1 haplotype variation were selected as haplotype tagging SNPs and analyzed for associated PC risk.
|
16189707 |
2005 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We explored the association between E-cadherin gene polymorphism and the risk of prostate cancer in a Japanese population.
|
15741307 |
2005 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
We found that CpG islands at GSTP1, APC, RASSF1a, PTGS2, and MDR1 were hypermethylated in >85% of prostate cancers and cancer cell lines but not in normal prostate cells and tissues; CpG islands at EDNRB, ESR1, CDKN2a, and hMLH1 exhibited low to moderate rates of hypermethylation in prostate cancer tissues and cancer cell lines but were entirely unmethylated in normal tissues; and CpG islands at DAPK1, TIMP3, MGMT, CDKN2b, p14/ARF, and CDH1 were not abnormally hypermethylated in prostate cancers.
|
15026333 |
2004 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that the -160 single nucleotide polymorphism in CDH1 is a low-penetrant prostate cancer susceptibility gene that might explain a proportion of familial and notably hereditary prostate cancer.
|
14961571 |
2004 |